Probi AB (publ) (STO: PROB)

Market Cap	3.99B
Revenue (ttm)	630.39M
Net Income (ttm)	10.88M
Shares Out	11.39M
EPS (ttm)	0.96
PE Ratio	366.40
Forward PE	139.03
Dividend	1.30 (0.37%)
Ex-Dividend Date	May 8, 2024

Volume	167
Average Volume	3,324
Open	349.00
Previous Close	349.00
Day's Range	349.00 - 350.00
52-Week Range	186.00 - 351.00
Beta	0.47
RSI	64.36
Earnings Date	Jan 28, 2025

About Probi AB

Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children’s, women’s, and senior health, as well as iron absorption. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beve...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 160
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: PROB

Financial Performance

In 2023, Probi AB's revenue was 627.69 million, an increase of 1.52% compared to the previous year's 618.29 million. Earnings were 16.82 million, a decrease of -58.60%.